tiprankstipranks
Thermo Fisher (DE:TN8)
XETRA:TN8

Thermo Fisher (TN8) Stock Price & Analysis

7 Followers

TN8 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€396.19 - €558.90
Previous Close€505
Volume30.00
Average Volume (3M)153.00
Market Cap
€189.69B
Enterprise Value€215.99B
Total Cash (Recent Filing)$7.25B
Total Debt (Recent Filing)$35.61B
Price to Earnings (P/E)35.0
Beta0.63
Jul 24, 2024
Dividend Yield0.27%
Share Statistics
EPS (TTM)14.38
Shares Outstanding381,716,323
10 Day Avg. Volume101
30 Day Avg. Volume153
Standard Deviation0.06
R-Squared0.00078
Alpha0.00893
Financial Highlights & Ratios
Price to Book (P/B)-14.99
Price to Sales (P/S)4.71
Price to Cash Flow (P/CF)43.10
P/FCF Ratio44.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.08
Enterprise Value/Gross Profit12.63
Enterprise Value/Ebitda29.19
Forecast
Price Target Upside14.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say
Financial PerformanceThermo Fisher Scientific delivered higher-than-expected earnings per share (EPS) of $5.11, surpassing the consensus estimate of $4.71.
Market PositionTMO remains in the top tier of Outperform-rated names, with the potential for meaningful EPS acceleration in 2024 and an attractive relative valuation for a high-quality multi-year compounder.
Mergers And AcquisitionsThe UK Competition and Markets Authority cleared TMO's acquisition of OLK, following a similar decision by Germany's Bundeskartellamt.
Bears Say
Financial PerformanceThe Life Sciences Solutions segment was weaker, down 12%, likely due to continued bioprocessing headwinds, China, and biotech funding issues.
GrowthSince the TMO-OLK deal announcement, OLK has seen growth slow down, primarily from declines in the service.
Market ConditionsRecovery ultimately still depends on pharma/biotech funding and China.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.49%26.39%17.77%55.35%
17.77% Other Institutional Investors
55.35% Public Companies and
Individual Investors

TN8 FAQ

What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest stock price was €396.19 and its highest was €558.90 in the past 12 months.
    What is Thermo Fisher’s market cap?
    Currently, no data Available
    When is Thermo Fisher’s upcoming earnings report date?
    Thermo Fisher’s upcoming earnings report date is Jul 24, 2024 which is in 11 days.
      How were Thermo Fisher’s earnings last quarter?
      Thermo Fisher released its earnings results on Apr 24, 2024. The company reported €4.721 earnings per share for the quarter, beating the consensus estimate of €4.351 by €0.37.
        Is Thermo Fisher overvalued?
        According to Wall Street analysts Thermo Fisher’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Thermo Fisher pay dividends?
          Thermo Fisher pays a Quarterly dividend of €0.36 which represents an annual dividend yield of 0.27%. See more information on Thermo Fisher dividends here
            What is Thermo Fisher’s EPS estimate?
            Thermo Fisher’s EPS estimate is €4.73.
              How many shares outstanding does Thermo Fisher have?
              Thermo Fisher has 381,716,300 shares outstanding.
                What happened to Thermo Fisher’s price movement after its last earnings report?
                Thermo Fisher reported an EPS of €4.721 in its last earnings report, beating expectations of €4.351. Following the earnings report the stock price went up 2.359%.
                  Which hedge fund is a major shareholder of Thermo Fisher?
                  Among the largest hedge funds holding Thermo Fisher’s share is PRIMECAP Management Co. It holds Thermo Fisher’s shares valued at 2B.
                    ---

                    Company Description

                    Thermo Fisher

                    Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services segments. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.
                    ---

                    TN8 Company Deck

                    ---

                    TN8 Earnings Call

                    Q1 2024
                    0:00 / 0:00
                    ---

                    TN8 Revenue Breakdown

                    53.76%53.76%23.28%16.95%10.28%
                    53.76% Laboratory Products and Biopharma Services
                    23.28% Life Sciences Solutions
                    16.95% Analytical Instruments
                    10.28% Specialty Diagnostics
                    tipranks
                    ---

                    TN8 Stock 12 Month Forecast

                    Average Price Target

                    €579.74
                    ▲(14.80% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"424":"€424","617":"€617","472.25":"€472.3","520.5":"€520.5","568.75":"€568.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":616.7149,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€616.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":579.7396201,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€579.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":552.282,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€552.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[424,472.25,520.5,568.75,617],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497.25,506.4396076923077,515.6292153846153,524.8188230769231,534.0084307692307,543.1980384615384,552.3876461538462,561.5772538461538,570.7668615384615,579.9564692307692,589.1460769230769,598.3356846153846,607.5252923076922,{"y":616.7149,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497.25,503.5953553923077,509.94071078461536,516.2860661769231,522.6314215692307,528.9767769615385,535.3221323538462,541.6674877461538,548.0128431384616,554.3581985307693,560.7035539230769,567.0489093153847,573.3942647076923,{"y":579.7396201,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497.25,501.4832307692308,505.71646153846154,509.9496923076923,514.1829230769231,518.4161538461539,522.6493846153846,526.8826153846154,531.1158461538462,535.349076923077,539.5823076923077,543.8155384615385,548.0487692307693,{"y":552.282,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":468.918,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.038,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":515.989,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":468.836,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.625,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455.464,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":488.631,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":506.906,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":529.475,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":536.42,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":534.721,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":539.818,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":497.25,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Thermo Fisher
                    Agilent
                    Abbott Laboratories
                    Amgen
                    Bristol-Myers Squibb

                    Best Analysts Covering TN8

                    1 Year
                    1 Year Success Rate
                    19/20 ratings generated profit
                    95%
                    1 Year Average Return
                    +23.14%
                    upgraded a buy rating 6 months ago
                    Copying Jack Meehan's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +23.14% per trade.
                    Popular Stocks
                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis